RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+58.11%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$8.26B
AUM Growth
+$8.26B
(+52%)
Cap. Flow
+$872M
Cap. Flow
% of AUM
10.56%
Top 10 Holdings %
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10
Top Buys
| 1 |
Shattuck Labs
STTK
|
$295M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
$212M |
| 3 |
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
|
$176M |
| 4 |
AbbVie
ABBV
|
$149M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$94.1M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$275M |
| 2 |
Amicus Therapeutics
FOLD
|
$56.7M |
| 3 |
Boston Scientific
BSX
|
$54.3M |
| 4 |
BioNTech
BNTX
|
$53.4M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$37.8M |
Sector Composition
| 1 | Healthcare | 95.01% |
| 2 | Technology | 0.52% |
| 3 | Financials | 0.46% |
| 4 | Consumer Staples | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $1.15B | 13.91% | 12,629,737 | – | – |
|
|
2
Amicus Therapeutics
FOLD
$2.34B
| $476M | 5.77% | 20,620,490 -2,455,317 | -11% | -$56.7M |
|
|
ALLK
3
DELISTED
Allakos
ALLK
| $373M | 4.52% | 2,667,451 +241,891 | +10% | +$33.9M |
|
4
Beam Therapeutics
BEAM
$1.66B
| $308M | 3.74% | 3,778,262 +451,000 | +14% | +$36.8M |
|
|
IGMS
5
DELISTED
IGM Biosciences
IGMS
| $302M | 3.66% | 3,425,455 | – | – |
|
|
6
Shattuck Labs
STTK
$47M
| $295M | 3.57% | +5,619,914 | New | +$295M |
|
7
argenx
ARGX
$43.6B
| $270M | 3.27% | 918,307 -70,161 | -7% | -$20.6M |
|
|
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $253M | 3.07% | 4,437,968 -336,950 | -7% | -$19.2M |
|
|
NVTA
9
DELISTED
Invitae Corporation
NVTA
| $220M | 2.66% | 5,263,309 +5,068,306 | +2,599% | +$212M |
|
10
ADC Therapeutics
ADCT
$345M
| $216M | 2.62% | 6,758,794 +405,700 | +6% | +$13M |
|
|
OSH
11
DELISTED
Oak Street Health, Inc.
OSH
| $179M | 2.17% | 2,925,711 +273,300 | +10% | +$16.7M |
|
|
MDVL
12
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $176M | 2.14% | +11,724,726 | New | +$176M |
|
13
Kymera Therapeutics
KYMR
$2.95B
| $169M | 2.04% | 2,720,489 -12,171 | -0.4% | -$755K |
|
14
Stoke Therapeutics
STOK
$1.08B
| $166M | 2.01% | 2,686,234 +136,728 | +5% | +$8.47M |
|
15
Replimune Group
REPL
$422M
| $152M | 1.84% | 3,993,399 +662,400 | +20% | +$25.3M |
|
|
16
AbbVie
ABBV
$372B
| $149M | 1.8% | +1,388,904 | New | +$149M |
|
|
ONEM
17
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $144M | 1.75% | 3,309,194 -35,500 | -1% | -$1.55M |
|
18
Scholar Rock
SRRK
$3.14B
| $141M | 1.7% | 2,896,589 -4,300 | -0.1% | -$209K |
|
19
Atara Biotherapeutics
ATRA
$84.6M
| $135M | 1.63% | 6,863,070 -75,800 | -1% | -$1.49M |
|
20
Gilead Sciences
GILD
$140B
| $133M | 1.61% | 2,288,846 -581,116 | -20% | -$33.9M |
|
21
Zentalis Pharmaceuticals
ZNTL
$122M
| $126M | 1.52% | 2,416,406 -16,002 | -0.7% | -$831K |
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $103M | 1.24% | 9,450,305 +1,138,672 | +14% | +$12.4M |
|
23
Krystal Biotech
KRYS
$4.27B
| $101M | 1.22% | 1,675,036 +173,091 | +12% | +$10.4M |
|
24
Sanofi
SNY
$121B
| $96.4M | 1.17% | 1,984,690 +241,642 | +14% | +$11.7M |
|
25
Regenxbio
RGNX
$451M
| $96.3M | 1.17% | 2,123,492 -104,674 | -5% | -$4.75M |
|